首页> 外文OA文献 >A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
【2h】

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing

机译:全基因组和转录组测序揭示了肺腺癌中的转化性KIF5B和RET基因融合

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The identification of the molecular events that drive cancer transformation is essential to the development of targeted agents that improve the clinical outcome of lung cancer. Many studies have reported genomic driver mutations in non-small-cell lung cancers (NSCLCs) over the past decade; however, the molecular pathogenesis of >40% of NSCLCs is still unknown. To identify new molecular targets in NSCLCs, we performed the combined analysis of massively parallel whole-genome and transcriptome sequencing for cancer and paired normal tissue of a 33-yr-old lung adenocarcinoma patient, who is a never-smoker and has no familial cancer history. The cancer showed no known driver mutation in EGFR or KRAS and no EML4-ALK fusion. Here we report a novel fusion gene between KIF5B and the RET proto-oncogene caused by a pericentric inversion of 10p11.22–q11.21. This fusion gene overexpresses chimeric RET receptor tyrosine kinase, which could spontaneously induce cellular transformation. We identified the KIF5B-RET fusion in two more cases out of 20 primary lung adenocarcinomas in the replication study. Our data demonstrate that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggest the chimeric oncogene as a promising molecular target for the personalized diagnosis and treatment of lung cancer.
机译:鉴定驱动癌症转化的分子事件对于开发靶向药物以改善肺癌的临床结果至关重要。在过去的十年中,许多研究报告了非小细胞肺癌(NSCLC)中的基因组驱动突变。然而,尚不清楚> 40%的NSCLCs的分子发病机理。为了确定NSCLC中的新分子靶标,我们对33岁的肺腺癌患者进行了大规模平行的全基因组和转录组测序分析,并分析了癌症的配对组织,该患者是从未吸烟者且无家族性癌症历史。该癌症在EGFR或KRAS中没有已知的驱动程序突变,也没有EML4-ALK融合。在这里,我们报道了一种KIF5B与RET原癌基因之间的新型融合基因,该融合基因是由10p11.22–q11.21的周向反转引起的。该融合基因过表达嵌合的RET受体酪氨酸激酶,可自发诱导细胞转化。在复制研究中,我们在20例原发性肺腺癌中的另外2例中鉴定了KIF5B-RET融合蛋白。我们的数据表明,NSCLCs的一个子集可能是由KIF5B和RET融合引起的,并表明嵌合癌基因是肺癌个性化诊断和治疗的有希望的分子靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号